The preliminary clinical experience with laparoscopic duodenojejunal bypass for treatment of type 2 diabetes mellitus in non-morbidly obese patients: the 1-year result in a single institute
Paik KY et al. – Laparoscopic duodenojejunal bypass (LDJB) demonstrated a glycemic control effect up to 1 year on type 2 diabetes mellitus (T2DM) in non–morbidly obese patients.Methods
- Twelve non–morbidly obese patients with T2DM underwent LDJB.
- Changes in fasting blood glucose, body mass index glycosylated hemoglobin (HbA1c), and dose of antidiabetic medications were recorded prospectively during a 1–year period.
- Reduction in HbA1c occurred 3 months after surgery and was maintained up to 1 year, and hyperglycemia was reversed within 1 month after surgery and remained controlled at 12 months.
- BMI decreased significantly 1 month after surgery and then remained steady through the year.
- Three patients (25.0 %) stopped antidiabetic medication, seven (58.3 %) patients maintained or decreased doses, and two (16.7 %) increased doses.
- Seven (58.3 %) patients had a decline in HbA1c.